Orchid Pharma Inks USD 80 Million Latin American Licensing Deal for Exblifep

Key numbers

Opportunity	USD 80MOver 10 Years
Market Cap	₹4,930.3 CrMid Cap
P/E TTM	568.83Sector 44.59
Day RSI	25.89Oversold Zone

Key highlights

• Exclusive rights granted to Laboratorio Libra for marketing and distribution in nine Latin American countries
• Partnership represents a potential USD 80 million opportunity over the initial 10-year term
• Exblifep is the first Indian-invented New Chemical Entity to secure both USFDA and EMA approvals
• Orchid Pharma will serve as the exclusive manufacturer and supplier of the finished dosage form
• Agreement targets serious hospital infections including HAP/VAP and complicated urinary tract infections

Strategic Expansion into Latin American Markets

Orchid Pharma Limited has expanded its global footprint for Exblifep through a long-term licensing and supply agreement with Uruguay-based Laboratorio Libra S.A. The deal encompasses nine territories: Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, and Uruguay. Libra will lead the registration and commercialisation efforts in these markets, while Orchid maintains its role as the primary manufacturer.

Exblifep is a novel carbapenem-sparing antibiotic combination specifically indicated for treating complicated urinary tract infections and hospital-acquired bacterial pneumonia caused by resistant Gram-negative pathogens. The partnership leverages Libra's established distribution network and regional regulatory expertise to address the growing challenge of antimicrobial resistance in the region.

Commercial Terms and Market Potential

• The partnership is expected to represent a commercial opportunity of approximately USD 80 million over the first 10 years.
• Libra receives exclusive rights to register, import, and market the product in the nine designated countries.
• Orchid Pharma will manufacture and supply the finished dosage form from its compliant facilities.
• Commercial launch in each specific market is contingent upon securing approvals from relevant national regulatory authorities.
• The agreement specifically targets high-demand clinical settings for ESBL-producing Gram-negative bacteria.

Contextualising Growth and Pipeline Milestones

The Latin American deal follows a substantial July 2026 agreement with Pharmasyntez JSC for the Russian market, valued at ₹1,480 crore. Orchid's IP strategy is backed by its 2025 acquisition of Allecra Therapeutics' assets, which solidified its control over Exblifep's global rights. Financially, the company reported a 75.9% year-on-year surge in revenue to ₹304.17 crore for the quarter ended June 2026, though net profit declined by 78.4% to ₹3.22 crore.

Operating margins stood at 4.6% during the same period. The stock is currently trading at a P/E of 568.83, reflecting significant market expectations for its NCE portfolio as it prepares for the commissioning of its ₹600 crore Jammu fermentation facility in 2027.

Leadership on the Regional Partnership

Extending Exblifep into Latin America is a priority for Orchid, and Libra is well placed to lead its introduction across these markets. Together, we aim to give clinicians in the region a new option for treating serious Gram-negative hospital infections.

What to watch next

• Completion of the 7-ACA fermentation manufacturing facility in Jammu by December 2026
• Commercial commissioning of the ₹600 crore Jammu plant slated for March 2027
• Regulatory approval filings and clearances for Exblifep across the nine Latin American jurisdictions
• Quarterly financial results announcement for the period ending September 2026

“We are honoured to partner with Orchid Pharma to bring Exblifep to Latin America, expanding access to an innovative therapeutic option for patients across the region while contributing to the response to the growing challenge of antimicrobial resistance.”

Orchid Pharma · financial snapshot

Share price	₹823.3
Market capitalisation	₹4,930.35 Cr
Revenue (annual)	₹811.33 Cr
Net profit (annual)	₹20.55 Cr
Revenue (latest quarter)	₹304.17 Cr+28.01% vs previous quarter
Net profit (latest quarter)	₹3.22 Cr-86.44% vs previous quarter
P/E (TTM)	568.83×Sector 44.59×
Promoter holding	74.45%+4.61% QoQ
FII holding	0.93%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.